Healthcare Distribution Alliance – Patients Move Us.
Share Print
banner capitol


HDA reviews key priority issues and advocates on behalf of its pharmaceutical distributor members for standards, public policies and business processes that ensure a safe and efficient supply chain.

  • COVID-19 Response

    The Healthcare Distribution Alliance and its primary pharmaceutical distributor members are closely monitoring the ongoing situation around the novel COVID-19 coronavirus.

  • Pharmaceutical Traceability

    HDA is now leading industry efforts to implement the 2013 Drug Supply Chain Security Act (DSCSA) that replaced a 50-state patchwork of pedigree requirements with one federal solution to trace prescription medications through the supply chain.

  • Importation of Prescription Medicines

    HDA opposes permitting the importation into the U.S. of pharmaceuticals sold or designated for sale in foreign countries. HDA firmly believes that allowing importation increases the likelihood of counterfeit or adulterated drugs entering the United States and will not ensure meaningful reductions in the cost of prescription drugs.

  • Prescription Drug Abuse and Diversion

    HDA and our primary pharmaceutical distributor members are committed to bringing industry and government together to tackle our nation’s complex prescription drug abuse and diversion epidemic, a serious healthcare challenge that threatens both patient safety and the security of the healthcare supply chain.

  • Taxes

    HDA opposes repeal of the Last in, First Out (LIFO) accounting method and establishment of gross receipts taxes. Healthcare distribution represents a high-volume, low-profit margin business that is impacted disproportionately under certain tax proposals, including repeal of LIFO and instituting gross receipts taxes.

  • Reimbursement Issues

    HDA supports the exclusion of customary prompt pay discounts from the calculation of the Average Sales Price (ASP) for Medicare Part B.

  • Distributor Licensure

    The introduction of counterfeit or adulterated medicines into the supply chain is a serious issue that could adversely affect the safety of prescription medicines and the health of patients. To that end, HDA strongly supports tough, rigorous and consistent standards for state licensing of pharmaceutical distributors as required under federal law.

  • Drug Shortages

    Drug shortages have challenged regulatory and supply chain stakeholders alike in recent years. While there are many factors that may result in a product being in short supply, HDA pharmaceutical distributor members play a central role in exchanging and coordinating information when a shortage occurs.

  • Emergency Preparedness and Response Efforts

    Pharmaceutical distributors have emergency preparedness plans in place to ensure continued operations in emergencies, and they actively collaborate with their supply chain partners to solve challenges created by a pandemic or severe emergency scenario.

  • Grassroots Advocacy

    HDA member companies' involvement in advocacy and legislative outreach is important to supporting, protecting and promoting the pharmaceutical distribution industry. As an organization that fosters productive partnerships between supply chain stakeholders and lawmakers, HDA facilitates this outreach by encouraging grassroots member participation in the legislative process.

The Vital Link in Healthcare

HDA's "Vital Link Toolkit" was created to inform and educate the public on the role of pharmaceutical distributors in the healthcare industry.


Read press releases, public testimony and executive statements about HDA's efforts on behalf of pharmaceutical distributors and the entire supply chain.

© 2020 Healthcare Distribution Alliance. All rights reserved.
HDA: E | C | C2 | NF | O365